Clinical Trials

ASCENT Trial for Metastatic Triple-Negative Breast Cancer

Immunomedics is currently sponsoring an international Phase 3 clinical trial of sacituzumab govitecan in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease. For more information on this clinical trial, please visit

TROPHY U-01 for Metastatic Urothelial Cancer

Immunomedics is recruiting for a Phase II trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies.  For more information visit

Compassionate Use Program

Immunomedics does not have a Compassionate Use Program for IMMU-132 at this time; however, patients with refractory/relapsed triple-negative breast cancer may be eligible for enrollment in the large ASCENT clinical trial ( Identifier: NCT02574455). Subjects are currently being recruited at 177 locations in the United States and Europe.